补益肝肾汤联合美多巴治疗帕金森患者的临床效果及对认知功能的影响

目的:探讨补益肝肾汤联合美多巴治疗帕金森(PD)患者的临床效果及对认知功能的改善作用。方法:选择2012年3月至2016年3月80例我院收治的PD伴轻度认知功能障碍患者并将其随机分作2组,对照组40例仅予美多巴片单药治疗,研究组40例在对照组的基础上另加服补益肝肾汤。治疗前后分别采用帕金森病综合评分量表(UPDRS)和简易精神量表(MMSE)对患者进行评估,评价和比较两组的疗效和不良反应的发生情况。结果:治疗后,研究组UPDRS总分明显低于对照组(P0.05);MMSE评分明显高于对照组(P0.05);总有效率明显高于对照组(P0.05);不良反应发生率与对照组比较差异无统计学意义(P0.05)。结论:补益肝肾汤联合美多巴治疗PD患者的临床效果优于美多巴片单药治疗,并可显著改善患者的认知功能障碍,且安全性高。

Clinical Effect of Tonify the Liver and Kidney combined with Madopar on the Parkinson's Patients and the Improvement on Cognitive Function

ABSTRACT Objective: To explore the clinical effect of tonify the liver and kidney combined with Madopar on the parkinson''s patients and improvement on the cognitive function. Methods: 80 cases of PD patients with mild cognitive impairment from March 2012 to March 2016 were selected and randomly divided into 2 groups, 40 cases in the control group were given Madopar tablets monotherapy, 40 cases in the research group were given tonify the liver and kidney on the basis of control group. Before and after treatment, the patients were assessed by Parkinson''s Disease Rating Scale (UPDRS) and mini mental scale (MMSE), and the curative effect and incidence of adverse reaction were observed and compared between two groups. Results: After treatment, the total score of UPDRS in research group was significantly lower than that of the control group (P < 0.05), and the MMSE score was significantly higher than that of the control group (P < 0.05), and the total effective rate was significantly higher than that of the control group(P<0.05), but no significant difference was found in the incidence of adverse reactions between two groups(P>0.05). Conclusion: Tonify the liver and kidney combined with Madopar was superior to Madopar tablets monotherapy in the treatment of patients with PD, which could improve the cognitive function with high safety.